News

Verastem will launch a U.S. phase 1/2a trial of oral KRAS G12D inhibitor VS-7375 after FDA IND clearance, with data to be ...
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate ...